ArticleScientific reports2025
Solid-phase microextraction of sweat components of patients positive for Sars-Cov-2 for identification of possible biomarkers.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Metabolomics is gaining consideration as a viable approach to diseases detection and even shows promising results in COVID-19 diagnosis. This work extends the study of the relationship between extractable sweat compounds and COVID-19 positive patients. Sweat samples were collected from 426 patients (126 positives and 300 negatives) recruited at Merida and Progreso (Yucatán, México) health centers. The composition of sweat was analyzed with a solid phase microextraction gas chromatography-mass spectrometry (SPME-GC-MS) method. The PLS-DA, with specificity and sensitivity percentages greater than 80%, revealed significant differences between the DI-SPME profiles of infected and non-infected patients. Six key peaks used in the classification model were annotated as undecanal, methyl palmitoleate, palmitic acid, methyl oleate, squalene, and methyl cerotate, based on NIST17 spectral matches (> 90%) and interpretation aided by retention index (RI) data. Palmitic acid and Methyl oleate signals were elevated in COVID-positive patients,while undecanal, methyl palmitoleate, squalene and methyl cerotate were detected in lower amounts in COVID-positive patients. The identified set of compounds may serve as potential biomarkers for COVID-19 disease, not only in serologic assessments but also in the development of non-invasive diagnostic approaches, such as sweat-based or volatilome-based testing, as well as for monitoring disease progression and patient recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.